The Pearsanta’s MET diagnostic test uses a blood-based biomarker for detecting mitochondrial DNA for diagnosing endometriosis ...

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, ...

Under the Second Amendment, the parties have extended the dates by which Aditxt shall complete the remaining $3 million in funding to Evofem through the purchase of 3,000 shares of Evofem’s F-1 ...

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is ...

Under the Agreement, Evofem and Pearsanta will collaboratively develop a comprehensive go-to-market strategy and MET commercial plan ahead of the planned U.S. launch in mid-2025. To date ...

Aditxt (NASDAQ: ADTX) , an innovation platform dedicated to accelerating promising health innovations, has reported that its Acquisition target, Evofem Biosciences (OTCQB: EVFM) , a women's health ...

SAN DIEGO, Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB ...

SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the second quarter and ...

In tandem with this financing arrangement, Aditxt has also invested in Evofem Biosciences (OTC:EVFM), Inc., purchasing 260 shares of Series F-1 Convertible Preferred Stock for $260,000. This ...

SAN DIEGO, September 09, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer ...